After examining the complex interplay between heart failure (HF) in its various clinical forms,
metabolic disorders like nonalcoholic fatty liver disease (NAFLD), and obstructive sleep …

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as an important
approach for the treatment of heart failure in patients with or without diabetes. Although the …

Heart failure (HF) represents a major public health concern with increasing prevalence
among aging populations, with multifactorial pathophysiology including inflammation …

The pathogenesis of diabetes mellitus (DM)-related cardiac dysfunction is thought to be
multifactorial, and possibly a key factor for the development of heart failure with preserved …

Abstract Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of medications
that reduce plasma glucose concentrations through an insulin-independent mechanism of …

Recent major clinical trials of the use of sodium–glucose cotransporter 2 (SGLT2) inhibitors
in patients with type 2 diabetes have shown that they reduce three‐point major adverse …

Type 2 diabetes mellitus (T2DM) and heart failure (HF) are multifactorial diseases sharing
common risk factors, such as obesity, hyperinsulinemia, and inflammation, with underlying …

Heart failure (HF) is an underappreciated complication of diabetes. HF occurs in individuals
with diabetes at higher rates, even in the absence of other HF risk factors such as coronary …

Heart failure with preserved ejection fraction (HFpEF) is a complex clinical syndrome with
high morbidity and increasing socio-economic burden, compounded by the lack of effective …

Background Updated recommendations for the treatment of heart failure with reduced
ejection fraction (HFrEF) include sodium-glucose cotransporter 2 (SGLT2) inhibitors and …